September 2021 - Page 3 of 5 - BioMedWire (BMW)

FridaySep 17, 2021 9:15 am

Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

Nemaura’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed for people with diabetes and prediabetes sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union, and Nemaura has submitted a premarket approval application to the U.S. FDA Nemaura continues to build a world-class management team Nemaura plans to launch a direct to consumer metabolic health program in 2021, using its glucose monitoring platform at the core of the program Nemaura has several patents (both filed and pending) and substantial trade secrets covering its technology platform…

FridaySep 17, 2021 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities

InMed Pharmaceuticals recently announced it has entered a definitive agreement to acquire 100% of BayMedica Inc. BayMedica is a private company that specializes in the manufacture and commercialization of rare cannabinoids Upon closing, the transaction will make InMed a global leader in the manufacturing of rare cannabinoids in addition to transforming it into a revenue-generating company Acquisition provides InMed with the complete flexibility across multiple manufacturing approaches On September 13, InMed Pharmaceuticals (NASDAQ: INM), a company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced it has signed a definitive agreement to acquire 100% of BayMedica…

FridaySep 17, 2021 9:00 am

Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concerns Tryp is preparing Phase 2a and Phase 2b clinical trials and expects to advance its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) platform in conjunction with research teams at the University of Florida and the University of Michigan The DEA recently recommended a significant increase in cannabis…

ThursdaySep 16, 2021 10:30 am

Young People’s Mental Health Boosted by Communal Recreational Activities

A new study conducted by researchers from the University of Oulu has found that communal leisure activities have positive effects on the mental health of young individuals. For the study, the experts in health sciences and psychiatry analyzed the link between psychiatric morbidity later in life and leisure activities of young individuals aged 15 and 16. The researchers found that socially active leisure time in young people was linked to a lower incidence of psychiatric disorders. This was especially evident in the case of substance abuse, anxiety disorders and mood disorders. In addition to this, the experts discovered that leisure…

WednesdaySep 15, 2021 1:43 pm

Potential for Psychedelic treatments Drives Mind Cure Health Inc.’s (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Strategy for Therapeutics Profitability

Canada-based life sciences company Mind Cure Health is developing a synthetic form of the psychedelic drug ibogaine as part of its efforts to take a leading position in the burgeoning market for mental health therapies Psychedelics, strengthened by new clinical research driving scientific and legislative openness to the drugs’ possible benefits under controlled conditions, are overcoming stigmas that arose from recreational use of the drug Mind Cure Health is developing a proprietary software-as-a-service (SaaS) platform known as iSTRYM to optimize the healing journey between patients and caregivers The company recently released its year-end financial report and an analysis outlining…

WednesdaySep 15, 2021 12:30 pm

Study Finds Fibromyalgia May Be Caused By Antibodies

A new study conducted by researchers at King’s College London, in collaboration with the Karolinksa Institute and the University of Liverpool, has found that fibromyalgia syndrome is an illness caused by the immune system. The researchers discovered that most symptoms of this syndrome were caused by antibodies that increased pain-sensing nerve activity in the body. Estimates show that one in every 40 individuals is affected by fibromyalgia syndrome globally, with figures showing that of this number, roughly 80% are female. The disease is commonly characterized by emotional distress, fatigue and widespread pain throughout an individual’s body. While children can also…

TuesdaySep 14, 2021 12:19 pm

New Prototype Device Eliminates Radiation Exposure from Breast Cancer Screening

Breast cancer is the second-leading cause of cancer death in women. Now scientists at the University of Waterloo have designed a system that could help save the lives of many women by routinely screening them for breast cancer without exposing them to radiation. This new and inexpensive technology uses artificial intelligence (“AI”) software and harmless microwaves to detect small early-stage tumors in minutes. Some studies have found that small tumors can be aggressive, which makes it even more important for women to begin screening for breast cancer regularly. A professor of electrical and computer engineering at the institution, Omar Ramahi…

TuesdaySep 14, 2021 9:48 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments

Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression Administering drug to mice resulted in an approximately 10% increase in neuron size and density Cybin is focused on progressing psychedelic therapeutics As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers that a single dose of psilocybin counteracts symptoms of depression (https://ibn.fm/NCORl) — companies operating in the space, including Cybin (NEO: CYBN) (NYSE American: CYBN), are ideally positioned to see significant benefits and growth. “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin…

MondaySep 13, 2021 2:10 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)…

MondaySep 13, 2021 1:05 pm

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for National Medical Products Administration Registration of Early-Warning Cancer Technology with a Record 11 Tumor Types Under Formal Medical Device Product Registration

AnPac Bio-Medical Science Co., Ltd. has developed its proprietary Cancer Differentiation Analysis (“CDA”) technology to detect biophysical signals as an alternative early disease indicator to blood-based biomarker testing for cancer The company has laboratories and R&D facilities in China equipped for CDA testing and cancer biochemical testing, as well as a CLIA/CAP accredited laboratory in the United States AnPac Bio recently held its 2021 technical symposium in China where KOLs from major hospitals and universities discussed new technologies for cancer detection and treatment. AnPac Bio-Medical Science (NASDAQ: ANPC) is moving forward with testing and registration of its multi-cancer screening technology…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: September 2021

Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities

Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Young People’s Mental Health Boosted by Communal Recreational Activities

Potential for Psychedelic treatments Drives Mind Cure Health Inc.’s (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Strategy for Therapeutics Profitability

Study Finds Fibromyalgia May Be Caused By Antibodies

New Prototype Device Eliminates Radiation Exposure from Breast Cancer Screening

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for National Medical Products Administration Registration of Early-Warning Cancer Technology with a Record 11 Tumor Types Under Formal Medical Device Product Registration

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search